NCT05515432View on ClinicalTrials.gov

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

March 7, 2023

Study Completion Date

June 6, 2023

Conditions

Chronic Kidney DiseaseRenal ImpairmentHealthy Volunteers

Interventions

DRUG

Single oral dose of BAY3283142 IR (immediate release) tablet

Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design

Trial Locations (1)

24105

CRS Clinical-Research-Services Kiel GmbH, Kiel